Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts.


Journal

The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246

Informations de publication

Date de publication:
11 2019
Historique:
received: 10 05 2019
revised: 09 07 2019
accepted: 29 07 2019
entrez: 2 11 2019
pubmed: 2 11 2019
medline: 7 7 2020
Statut: ppublish

Résumé

Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in Andhra Pradesh and Gujarat in 2009 introduced HPV vaccination in public health services in India. Following a few deaths in these projects, although subsequently deemed unrelated to vaccination, HPV vaccination in research projects was suspended. This suspension by default resulted in some participants in a trial evaluating two versus three doses receiving only one dose. Since 2016, the successful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects of a single dose providing protection, and future availability of an affordable Indian vaccine shows promise for future widespread implementation and evaluation of HPV vaccination in India.

Identifiants

pubmed: 31674322
pii: S1470-2045(19)30531-5
doi: 10.1016/S1470-2045(19)30531-5
pii:
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e637-e644

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2019 World Health Organization. Published by Elsevier Ltd. All rights reserved. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Rengaswamy Sankaranarayanan (R)

RTI International India, New Delhi, India; International Agency for Research on Cancer, World Health Organization, Lyon, France.

Partha Basu (P)

International Agency for Research on Cancer, World Health Organization, Lyon, France. Electronic address: basup@iarc.fr.

Prabhdeep Kaur (P)

National Institute of Epidemiology, Indian Council of Medical Research, Chennai, India.

Rajesh Bhaskar (R)

Department of Health and Family Welfare, Government of Punjab, Chandigarh, India.

Gurinder Bir Singh (GB)

Department of Health and Family Welfare, Government of Punjab, Chandigarh, India.

Phumzay Denzongpa (P)

Human Services and Family Welfare Department, Government of Sikkim, Gangtok, India.

Rajesh K Grover (RK)

Delhi State Cancer Institute, Delhi, India.

Paul Sebastian (P)

Tata Trusts, Mumbai, India.

Tapan Saikia (T)

Prince Aly Khan Hospital, Mumbai, India.

Kunal Oswal (K)

Tata Trusts, Mumbai, India.

Rishav Kanodia (R)

Tata Trusts, Mumbai, India.

Amantia Dsouza (A)

Tata Trusts, Mumbai, India.

Ravi Mehrotra (R)

National Institute of Cancer Prevention and Research, Indian Council of Medical Research, Noida, India.

Goura Kishor Rath (GK)

National Cancer Institute, All India Institute of Medical Sciences, Jhajjar Campus, Badsa, Haryana, India; Dr B R Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.

Viniita Jaggi (V)

Delhi State Cancer Institute, Delhi, India.

Sundram Kashyap (S)

Delhi State Cancer Institute, Delhi, India.

Ishu Kataria (I)

RTI International India, New Delhi, India.

Roopa Hariprasad (R)

National Institute of Cancer Prevention and Research, Indian Council of Medical Research, Noida, India.

Peter Sasieni (P)

Kings Clinical Trials Unit, King's College London, London, UK.

Neerja Bhatla (N)

Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.

Preetha Rajaraman (P)

Office of Global Affairs, Department of Health and Human Services, Washington, DC, USA.

Edward L Trimble (EL)

Global HPV and Cervical Cancer Research and Control, National Cancer Institute, Rockville, MD, USA.

Soumya Swaminathan (S)

World Health Organization, Geneva, Switzerland.

Arnie Purushotham (A)

King's Health Partners Integrated Cancer Centre, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH